Ultraproct N Adverse Reactions

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Full Prescribing Info

Adverse Reactions

After prolonged therapy with Ultraproct N (more than four weeks), there is a risk that the patient may develop local skin alterations, such as atrophy, striae or telangiectasias.
Cream: The incidence of the undesirable effects was calculated from pooled clinical trial data involving 661 patients.
Skin and subcutaneous tissue disorders: Uncommon (≥1/1,000 to <1/100): Allergic skin reactions to any of the excipients.
General disorders and administration site conditions: Common (≥1/100 to <1/10): Application site burning.
Uncommon (≥1/1,000 to <1/100): Application site irritation.
Suppository: The incidence of the undesirable effects was calculated from pooled clinical trial data involving 367 patients.
Skin and subcutaneous tissue disorders: Not known (frequency cannot be estimated from the available data): Allergic skin reactions to any of the excipients.
General disorders and administration site conditions: Common (≥1/100 to <1/10): Application site burning.
Uncommon (≥1/1,000 to <1/100): Application site irritation.

View ADR Monitoring Form

Ultraproct N Adverse Reactions

Manufacturer:

Karo Pharma

Distributor:

DKSH